The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | Combining menin/FLT3/BCL2 inhibition as a treatment approach in FLT3/NPM1 double mutated AML
Michael Andreeff, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses ongoing research exploring the possibility of combining BCL2 inhibitors, FLT3 inhibitors and menin inhibitors as a novel treatment approach for patients with FLT3/NPM1 double mutated acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
